All In Biotech

Drug Trial Radar · NCT06986772

TGRX-678 Pharmacokinetic Mass Balance

[14C]TGRX-678 Mass Balance Study in Chinese Healthy Male Adults

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Jul 7, 2025

Primary completion

Aug 17, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
The First Affiliated Hospital of Soochow University
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a pharmacokinetic study for \[14C\]TGRX-678 on mass balance to evaluate distribution, metabolism and excretion of TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • [14C]TGRX-678Drug

    Healthy subjects will be given TGRX-678 240 mg orally on day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urine radioactivityTime frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing
  2. Fecal radioactivityTime frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing
  3. Plasma AUC (Area under curve) percentageTime frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing
  4. Urine %DoseTime frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing
  5. Fecal %DoseTime frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing
  6. Plasma CmaxTime frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing
  7. Plasma TmaxTime frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing
  8. Plasma AUC(0-t)Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.